Clinical Trial Update: Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients

View source ↗

Summary

A completed clinical trial assessing voriconazole as prophylaxis to prevent aspergillosis in lung transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Aspergillosis

Drugs mentioned

• VFEND (Voriconazole)

Snippet

Sponsor: University of Pittsburgh | Conditions: Post Lung Transplantation | Status: COMPLETED